help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, D. G.
Right arrow Articles by Goodner, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, D. G.
Right arrow Articles by Goodner, C. J.

Endocrinology, Vol 96, 370-374, Copyright © 1975 by Endocrine Society

ARTICLES

Inhibition of glucagon and insulin secretion by somatostatin in the rat pancreas perfused in situ

DG Johnson, JW Ensinck, D Koerker, J Palmer and CJ Goodner

Perfusion of growth hormone inhibitory factor (somatostatin) into rat pancreas inhibited secretion of glucagon and insulin into medium containing 5.5 mM glucose. A 15-min infusion of arginine (20 mM) greatly increased glucagon and insulin secretion. When perfused simultaneously with arginine, somatostatin (55 nM) abolished the increase in glucagon secretion. The acute phase of insulin secretion in response to arginine was attenuated by somatostatin, and subsequent secretion was decreased to control levels. Pretreatment for 5 min with somatostatin blocked even acute-phase insulin secretion in response to arginine. Somatostatin did not affect basal or glucose-stimulated secretion of insulin from rat pancreatic islets isolated by the collagenase technique. Arginine-stimulated secretion of insulin was enhanced by somatostatin in isolated islets. These results demonstrate a direct effect of somatostatin on the pancreas to inhibit secretion of glucagon and insulin. The failure of somatostatin to inhibit insulin secretion in pancreatic islets may be due to alterations in the beta cells produced by the isolation procedure. It is also possible that the effect of somatostatin on insulin secretion may be mediated indirectly.


This article has been cited by other articles:


Home page
 J Biomol ScreenHome page
Weizhen Wu, Jin Shang, Yue Feng, C. M. Thompson, S. Horwitz, J. R. Thompson, E. D. Macintyre, N. A. Thornberry, K. Chapman, Y.-P. Zhou, et al.
Identification of Glucose-Dependent Insulin Secretion Targets in Pancreatic {beta} Cells by Combining Defined-Mechanism Compound Library Screening and siRNA Gene Silencing
J Biomol Screen, February 1, 2008; 13(2): 128 - 134.
[Abstract] [PDF]

Home page
 ScienceHome page
G Boden, M. Sivitz, O. Owen, N Essa-Koumar, and J. Landor
Somatostatin suppresses secretin and pancreatic exocrine secretion
Science, October 10, 1975; 190(4210): 163 - 165.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1975 by The Endocrine Society